IKT

Inhibikase Therapeutics, Inc.

IKT | $1.64 3.8% 3.66% 62K

(0.0% 1d) (-18.3% 1m) (-43.3% 1y) (0.0% 2d) (18.4% 3d) (-8.3% 7d) (-21.29% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 10,622,024
http://www.inhibikase.com
Sec Filling | Patents | 3 employees

(US) Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. The company was founded by Milton Werner in September 2008 and is headquartered in Atlanta, GA.

batteries battery infectious disease c-abl treatment

add to watch list Paper trade email alert is off

Press-releases

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Published: 2024-04-18 (Crawled : 20:00) - globenewswire.com
IKT | $1.64 3.8% 3.66% 62K

Health Technology

| -10.95% | O: 0.95% H: 0.47% C: -3.77%
update therapeutics development

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
IKT | $1.64 3.8% 3.66% 62K

Health Technology

| -13.02% | O: -0.93% H: 7.04% C: 0.94%
fda meeting hypertension therapeutics

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Published: 2024-03-27 (Crawled : 20:00) - globenewswire.com
IKT | $1.64 3.8% 3.66% 62K

Health Technology

| -18.7% | O: -5.22% H: 12.15% C: -0.92%
year therapeutics financial results

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Published: 2024-03-07 (Crawled : 13:30) - globenewswire.com
IKT | $1.64 3.8% 3.66% 62K

Health Technology

| -22.41% | O: 0.41% H: 2.89% C: 0.0%
conference alzheimer’s update international disorders neurological parkinson’s trial therapeutics

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
IKT | $1.64 3.8% 3.66% 62K

Health Technology

| -15.77% | O: 4.5% H: 1.29% C: -6.9%
fda meeting therapeutics

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
Published: 2024-02-07 (Crawled : 13:00) - globenewswire.com
IKT | $1.64 3.8% 3.66% 62K

Health Technology

| -37.25% | O: -9.06% H: 5.35% C: 0.37%
fda approval blood meeting gastrointestinal therapeutics

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
Published: 2024-01-29 (Crawled : 14:00) - globenewswire.com
IKT | $1.64 3.8% 3.66% 62K

Health Technology

| -36.82% | O: 1.01% H: 11.04% C: 7.36%
publication therapeutics results

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
Published: 2024-01-16 (Crawled : 21:00) - globenewswire.com
IKT | $1.64 3.8% 3.66% 62K

Health Technology

| 6.25% | O: -3.98% H: 0.0% C: -2.37%
therapeutics financial

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Published: 2023-12-19 (Crawled : 13:30) - globenewswire.com
IKT | $1.64 3.8% 3.66% 62K

Health Technology

| 37.5% | O: 4.41% H: 0.7% C: -2.82%
update therapeutics

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
Published: 2023-12-04 (Crawled : 13:30) - globenewswire.com
IKT | $1.64 3.8% 3.66% 62K

Health Technology